In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem ...
The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...
The newly combined company will focus on moving Kadimastem's AstroRx, NLS's DOXA platform, and other therapies through ...
Our pipeline includes programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and ...
Some diseases are a result of the loss of specific cells, such as the loss of motor neurons in amyotrophic lateral sclerosis (ALS), the loss of dopaminergic ... the recipient is affected by the age of ...
With its ability to improve neuron health, experimental drug NU-9 has already shown promise in reversing amyotrophic lateral ...
Trias E, Ibarburu S, Barreto-Núñez R, et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral ...